Abstract
Introduction

Biologics have been widely used for treating RA. In Japan, three kinds of anti-TNF agents "infliximab", "etanercept", and "adalimumab", as well as one anti-interleukin-6 receptor (IL-6R) agent "tocilizumab" are available. However, the safety of these agents has not been adequately established in embryos and fetuses. No controlled studies have been conducted to determine the risk of the administration of these agents to pregnant RA patients. Some reports suggest that anti-TNF agents are not associated with embry otoxicity and teratogenicity (1-3). In rats and rabbits, no malformation was induced even after exposure to high doses (up to 60-100 times) of etanercept (4). Food and Drug Administration (FDA) classified etanercept in Category B for
risk levels in pregnant patients. There are some studies, which report successful outcome of etanercept treatment in pregnant RA patients (1) (2) (3) 5 i g u r e 1 . Cl i n i c a l c o u r s e o f t h e p a t i e n t . E t a n e r c e p t t r e a t me n t wa s d i s c o n t i n u e d a t 6 we e k s o f p r e g n a n c y . T h r e e mo n t h l a t e r , a r t h r i t i s b e c a me wo r t h a n d we r e s t a r t e d i t a t 2 0 we e k s o f p r e g n a n c y . 
